Aitia has accepted an invitation to join the Global Neurodegeneration Proteomics Consortium (GNPC), a global effort co-founded by Johnson & Johnson and Gates Ventures to develop large harmonized databases of multiomics and clinical outcomes from tens of thousands of patients suffering from neurodegenerative diseases such as Alzheimer’s, Parkinson’s, amyotrophic lateral sclerosis (ALS), and frontotemporal dementia.
“The impressive work the GNPC has done already in building such robust human-based datasets provides the ideal opportunity for us to apply our causal AI REFS engine and the Gemini Digital Twins it produces,” said Colin Hill, CEO. “We hope to contribute a more comprehensive biology-based knowledge of neurodegenerative disease mechanisms to the Consortium, ultimately supporting more successful diagnostics and therapeutics discovery and development.”
More information about the GNPC can be found at https://www.neuroproteome.org